AVR vs. BVS, IRMD, AVNS, AXGN, SIBN, KIDS, NNOX, TMCI, SMLR, and TCMD
Should you be buying Anteris Technologies Global stock or one of its competitors? The main competitors of Anteris Technologies Global include Bioventus (BVS), Iradimed (IRMD), Avanos Medical (AVNS), AxoGen (AXGN), SI-BONE (SIBN), OrthoPediatrics (KIDS), Nano-X Imaging (NNOX), Treace Medical Concepts (TMCI), Semler Scientific (SMLR), and Tactile Systems Technology (TCMD). These companies are all part of the "medical equipment" industry.
Anteris Technologies Global vs.
Bioventus (NYSE:BVS) and Anteris Technologies Global (NASDAQ:AVR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, community ranking, profitability and dividends.
Bioventus received 26 more outperform votes than Anteris Technologies Global when rated by MarketBeat users. However, 100.00% of users gave Anteris Technologies Global an outperform vote while only 62.50% of users gave Bioventus an outperform vote.
Anteris Technologies Global has lower revenue, but higher earnings than Bioventus.
Bioventus presently has a consensus price target of $15.00, indicating a potential upside of 61.64%. Anteris Technologies Global has a consensus price target of $16.50, indicating a potential upside of 175.00%. Given Anteris Technologies Global's stronger consensus rating and higher probable upside, analysts clearly believe Anteris Technologies Global is more favorable than Bioventus.
62.9% of Bioventus shares are owned by institutional investors. 32.9% of Bioventus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Anteris Technologies Global has a net margin of 0.00% compared to Bioventus' net margin of -7.11%. Bioventus' return on equity of 15.61% beat Anteris Technologies Global's return on equity.
In the previous week, Anteris Technologies Global had 9 more articles in the media than Bioventus. MarketBeat recorded 13 mentions for Anteris Technologies Global and 4 mentions for Bioventus. Anteris Technologies Global's average media sentiment score of 0.77 beat Bioventus' score of 0.47 indicating that Anteris Technologies Global is being referred to more favorably in the news media.
Summary
Anteris Technologies Global beats Bioventus on 8 of the 14 factors compared between the two stocks.
Get Anteris Technologies Global News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Anteris Technologies Global Competitors List
Related Companies and Tools
This page (NASDAQ:AVR) was last updated on 1/10/2025 by MarketBeat.com Staff
